- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02752139
Cerebral Hemodynamics in Sleep Disorders
November 26, 2018 updated by: Yi Yang
The purpose of this study is to determine the relationship between sleep disorders and cerebral hemodynamics.
Study Overview
Status
Completed
Conditions
Detailed Description
Sleep disorders continue to be the most unrecognized modifiable risk factor for stroke.
The relationship between sleep disorders and vascular risk factors and stroke has been well-documented but not fully understood.
The investigators hypothesize hemodynamics impairment to be its potential mechanism.
It has been reported that sleep-related breathing disorder, a type of sleep disorders, contributed as a risk factor for stroke through hemodynamic and hematologic changes.
The purpose of this study is to determine the relationship between different kind of sleep disorders and cerebral hemodynamics, including OSHAS, RLS, RBD, narcolepsy, etc.
The dynamic cerebral auto-regulation (dCA) and Transcranial Doppler (TCD) will be used to evaluate cerebral hemodynamics.
Study Type
Observational
Enrollment (Actual)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jilin
-
Changchun, Jilin, China, 130000
- First Hospital of Jilin University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The investigators conducted a prospective study of consecutive patients with sleep disorders treated at the Department of Neurology, First Hospital of Jilin University, China, from March 2016 to March 2017.
Each patient was diagnosed with intrinsic sleep disorders by two neurologists according to the Diagnostic Criteria for Sleep Dyssomnias.
Description
Inclusion Criteria:
- patients with sleep disorders
- meet the Diagnostic Criteria for Sleep Dyssomnias
- sufficient bilateral temporal bone windows for insonation of the MCA
Exclusion Criteria:
- middle cerebral artery (MCA) and/or other intracranial and/or extracranial major vascular 4 stenosis/occlusion, as diagnosed by a transcranial Doppler
- having a prior symptomatic cerebral vascular disease
- current arrhythmia, hyperthyroidism, anemia and unstable blood pressure, which may undermine hemodynamic stability
- inability to cooperate sufficiently to complete the dCA examination
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
patients with sleep disorders
|
normal individuals without sleep disorders
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
phase difference(PD) in degree
Time Frame: 6 months
|
A dynamic cerebral auto-regulation parameter derived from transfer function analysis.Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler.
Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size.
Transfer function analysis will be used to derive the autoregulatory parameters.
|
6 months
|
the rate of recovery of cerebral blood flow velocity
Time Frame: 6 months
|
A dynamic cerebral auto-regulation parameter derived from transfer function analysis.The details are same as outcome 1
|
6 months
|
gain in cm/s/mmHg
Time Frame: 6 months
|
A dynamic cerebral auto-regulation parameter derived from transfer function analysis.The details are same as outcome 1
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
mean MCA blood flow velocity (mCBFV) changes from supine to upright position
Time Frame: 6 months
|
6 months
|
pulsatility index (PI) changes from supine to upright position
Time Frame: 6 months
|
6 months
|
resistance index (RI) changes from supine to upright position
Time Frame: 6 months
|
6 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
scores of Pittsburgh sleep quality index(PSQI)
Time Frame: 6 months
|
6 months
|
scores of Hamilton Anxiety Scale(HAMA)
Time Frame: 6 months
|
6 months
|
scores of Hamilton Depression Scale(HAMD)
Time Frame: 6 months
|
6 months
|
Polysomnography(PSG)
Time Frame: within 6 months
|
within 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2016
Primary Completion (Actual)
August 1, 2018
Study Completion (Actual)
October 26, 2018
Study Registration Dates
First Submitted
March 7, 2016
First Submitted That Met QC Criteria
April 22, 2016
First Posted (Estimate)
April 26, 2016
Study Record Updates
Last Update Posted (Actual)
November 27, 2018
Last Update Submitted That Met QC Criteria
November 26, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHSD-01-R
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Disorders, Intrinsic
-
Merck Sharp & Dohme LLCCompletedMental Disorders | Dyssomnias | Sleep Initiation and Maintenance Disorders | Sleep Disorders | Sleep Disorder, Intrinsic
-
Merck Sharp & Dohme LLCCompletedDyssomnias | Sleep Disorders | Mental Disorder | Sleep Initiation and Maintenance Disorder; Elderly | Sleep Disorder, Intrinsic
-
SleepUp Tecnologia em Saúde LtdaActive, not recruiting
-
Boehringer IngelheimCompletedSleep Initiation and Maintenance Disorders
-
St. Olavs HospitalNorwegian University of Science and TechnologyCompleted
-
Columbia UniversityCompleted
-
Koko Home, Inc.Stanford UniversityRecruitingSleep Disorder | Insomnia | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Sleep HygieneUnited States
-
DreemCompletedSleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Insomnia, SecondaryUnited States
-
Eunice Kennedy Shriver National Institute of Child...Sanofi-SynthelaboCompletedSleep Disorder | InsomniaUnited States
-
Neurovalens Ltd.The Hong Kong Polytechnic University; University of UlsterCompletedInsomnia | Sleep DisturbanceHong Kong, United Kingdom